Journal of Clinical Endocrinology & Metabolism, Vol 80, 1526-1531, Copyright © 1995 by Endocrine Society

ARTICLES

Prismatic cases: Laron syndrome (primary growth hormone resistance) from patient to laboratory to patient

Z Laron
Pediatric Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center of Israel, Tel Aviv.

Clinical investigations started in 1958 of a group of children with characteristics resembling GH deficiency, but who had extremely high levels of plasma GH, led to the description of the syndrome of primary GH resistance or insensitivity (Laron syndrome), the discovery of its molecular defect, and the clinical application of biosynthetic insulin- like growth factor-I. This syndrome is a unique model that enables study of the GH receptor, its signal transduction, and the comparison between the effects of GH and insulin-like growth factor-I.

This article has been cited by other articles:

				J. D. Kopple, G. Brunori, M. Leiserowitz, and D. Fouque Growth hormone induces anabolism in malnourished maintenance haemodialysis patients Nephrol. Dial. Transplant., May 1, 2005; 20(5): 952 - 958. [Abstract] [Full Text] [PDF]

				J. Xu, S. Ji, D. Y Venable, J. L Franklin, and J. L Messina Prolonged insulin treatment inhibits GH signaling via STAT3 and STAT1 J. Endocrinol., March 1, 2005; 184(3): 481 - 492. [Abstract] [Full Text] [PDF]

				Z. Laron Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003 J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1031 - 1044. [Abstract] [Full Text] [PDF]

				C. A. Benbassat, V. Eshed, M. Kamjin, and Z. Laron Are Adult Patients with Laron Syndrome Osteopenic? A Comparison between Dual-Energy X-Ray Absorptiometry and Volumetric Bone Densities J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4586 - 4589. [Abstract] [Full Text] [PDF]

				S. J. Frank Minireview: Receptor Dimerization in GH and Erythropoietin Action--It Takes Two to Tango, But How? Endocrinology, January 1, 2002; 143(1): 2 - 10. [Abstract] [Full Text] [PDF]

				N. Mauras, V. Martinez, A. Rini, and J. Guevara-Aguirre Recombinant Human Insulin-Like Growth Factor I Has Significant Anabolic Effects in Adults with Growth Hormone Receptor Deficiency: Studies on Protein, Glucose, and Lipid Metabolism J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3036 - 3042. [Abstract] [Full Text]

				The Essential Role of IGF-I: Lessons from the Long-Term Study and Treatment of Children and Adults with Laron Syndrome J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4397 - 4404. [Abstract] [Full Text]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				S. Ji, R. Guan, S. J. Frank, and J. L. Messina Insulin Inhibits Growth Hormone Signaling via the Growth Hormone Receptor/JAK2/STAT5B Pathway J. Biol. Chem., May 7, 1999; 274(19): 13434 - 13442. [Abstract] [Full Text] [PDF]

				Z. Laron and A. Galatzer A Comment on Normal Intelligence in Growth Hormone Receptor Deficiencya J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4528 - 4528. [Full Text]

				J. G. Buchlis, L. Irizarry, B. C. Crotzer, B. J. Shine, L. Allen, and M. H. MacGillivray Comparison of Final Heights of Growth Hormone-Treated Vs. Untreated Children with Idiopathic Growth Failure J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1075 - 1079. [Abstract] [Full Text]

				B. Kristrom, C. Jansson, S. Rosberg, and K. Albertsson-Wikland Growth Response to Growth Hormone (GH) Treatment Relates to Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Short Children with Various GH Secretion Capacities J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2889 - 2898. [Abstract] [Full Text] [PDF]

				Z. Laron Short Stature Due to Genetic Defects Affecting Growth Hormone Activity N. Engl. J. Med., February 15, 1996; 334(7): 463 - 466. [Full Text]